NKILT Therapeutics, Inc., is a new cell therapy biotech developing a novel approach of engineering Natural Killer (NK) cells, and other immune cells, to directly target leukemias and solid tumors. We have In vitro PoC confirmed with T cells and NK cells. Our approach is based on the novel Chimeric ILT-Receptor (CIR™), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers). Our initial armored CIR™NK cells will be able to exquisitely target and directly kill cancer cells but will also activate innate immunity and directly target the tumor’s defense mechanisms. The first indication will be Acute Myeloid Leukemia (AML) as a pre-clinical/clinical proof of concept, while our core focus is to expand to a large array of solid tumors such as Colorectal Cancer (CRC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Endometrial Cancer, and more HLA-G+ tumors.
